Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of chronic lymphocytic leukemia (CLL) that meets the following criteria at any point prior to study entry:
• * Peripheral blood absolute blood count greater than 5,000/mm\^3
• * Lymphocytosis must comprise small to moderate size lymphocytes with no more than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically
• * Phenotypically characterized B-cell CLL
• * Splenomegaly, hepatomegaly, or lymphadenopathy not required for CLL diagnosis
• Must have bone marrow biopsy within 4 weeks of study entry showing cellularity of at least 25% of intratrabecular space and lymphocytes accounting for no more than 30% of nucleated cells
• PATIENT CHARACTERISTICS:
• Age:
• 18 to 65
• Performance status:
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• See Disease Characteristics
• Absolute neutrophil count at least 1,000/mm\^3
• Hemoglobin at least 11 g/dL
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 2 mg/dL (unless secondary to tumor)
• AST or ALT less than 3 times upper limit of normal
• Hepatitis B surface antigen negative
• Hepatitis C RNA negative
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• Left ventricular ejection fraction at least 45% by echocardiogram or MUGA
• Pulmonary:
• DLCO, FEV\_1, and FVC greater than 50% of predicted
• Other:
• No active infection requiring oral or IV antibiotics
• No other prior malignancy within the past two years except basal cell skin cancer or carcinoma in situ of the cervix
• HIV negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Prior monoclonal antibody CD52 allowed if at least partial remission was achieved with last treatment
• Chemotherapy:
• No more than 2 prior chemotherapy regimens
• At least 3 weeks since prior chemotherapy
• No more than 8 courses of prior fludarabine therapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified